+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Ocular Melanoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 150 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294529
The ocular melanoma market size was valued at USD 1.82 billion in 2026 and is estimated to grow from USD 1.93 billion in 2027 to reach USD 2.64 billion by 2032, at a CAGR of 6.44% during the forecast period (2027-2032). This report is Segmented by Disease Site (Uveal Melanoma, and Conjunctival Melanoma), Disease Stage (Primary Ocular Melanoma, and More), Treatment Type (Radiation, Surgical, Laser, Immunotherapy, and More), Drug Class (Immune Checkpoint Inhibitors, and More), End User (Hospitals, Ophthalmology, and More), and Geography (North America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Ocular Melanoma Market Trends and Insights

Expanding Use of Liver-Directed Therapy for Hepatic-Dominant Metastases

Hepatic metastases occur in up to 90% of patients with metastatic uveal melanoma, making liver control a key treatment priority. This disease pattern expands the role of liver-directed therapies in the ocular melanoma market, particularly for patients with unresectable hepatic disease. HEPZATO Kit recorded 140% procedure volume growth in 2025, while Delcath targeted at least 28% additional volume growth in 2026. By mid-2026, Delcath reported 31 active Risk Evaluation and Mitigation Strategy (REMS)-certified centers and more than 50 sites in activation discussions. The 2026 European Society for Medical Oncology-European Reference Network for Rare Adult Solid Cancers (ESMO-EURACAN) guideline included CHEMOSAT as a recommended liver-directed option. A Phase 2 Moffitt study is assessing sequential percutaneous hepatic perfusion (PHP) followed by tebentafusp, which may strengthen the role of liver-directed chemotherapy in combination treatment.

Rising Adoption of Biomarker-Guided Immunotherapy

Biomarker-guided treatment is creating distinct treatment pathways for patients with human leukocyte antigen (HLA)-A*02:01-positive and HLA-A*02:01-negative disease. KIMMTRAK reported a 16% five-year overall survival rate, compared with 8% in the control arm among eligible patients, and a median overall survival of 21.6 months, compared with 16.9 months. In OptimUM-02, darovasertib plus crizotinib reported a 37.1% objective response rate, compared with 5.8% for investigator’s choice in HLA-A*02:01-negative metastatic uveal melanoma. The combination arm also recorded five complete responses, while the control arm reported none. These results increase the importance of HLA testing before systemic treatment begins. Food and Drug Administration (FDA) Breakthrough Therapy Designation and Real-Time Oncology Review can also shorten development timelines for therapies targeting this rare indication.

Extreme Disease Rarity and Concentrated Specialist Capacity

Uveal melanoma affects fewer than 10 people per million annually in North America and Western Europe, limiting the addressable patient population. This rarity constrains procedure volumes despite improvements in disease awareness, reimbursement, and therapy access. Fewer than 40 specialized or Risk Evaluation and Mitigation Strategy (REMS)-certified centers in the United States provide diagnosis and treatment, resulting in a highly concentrated care delivery model. HEPZATO administration requires interventional radiology capabilities, specialized catheter and filtration systems, and certified perfusion staff. Delcath reported an average of 0.75 new patients per site per month in early 2026, compared with a full-year average of 0.5 patients per site per month in 2025. These capacity constraints are more significant in Asia-Pacific and South America due to limited ocular oncology specialist availability.

Other drivers and restraints analyzed in the detailed report include:

  1. Shift From Enucleation Toward Globe-Sparing Radiotherapy
  2. Increasing Use of Molecular Prognostic Testing
  3. HLA-A*02:01 Eligibility Limits for Tebentafusp

Segment Analysis

Uveal melanoma held 86.12% of the ocular melanoma market share in 2026, supported by its higher incidence than other primary intraocular cancers and the availability of HEPZATO Kit and tebentafusp for metastatic disease. These therapies generated more than USD 500 million in annual net revenue by 2026. At least 20 active trials across adjuvant, neoadjuvant, and metastatic settings continue to support pipeline development and adoption at academic centers.

Conjunctival melanoma is projected to grow at a 9.22% compound annual growth rate (CAGR) through 2032, driven by the absence of approved pharmacological therapies and the need for systemic treatment options. A retrospective multicenter study of 16 patients reported a 63% objective response rate with immune checkpoint inhibitors, while 88% avoided orbital exenteration. Its BRAF and NF1 profiles often resemble cutaneous melanoma, supporting biology-based treatment escalation.

Primary ocular melanoma accounted for 44.93% of the ocular melanoma market size in 2026. Newly diagnosed patients receive plaque brachytherapy, proton beam radiation, surgery, and emerging neoadjuvant treatments. This consistent patient flow supports demand for primary-stage treatment services and sustains the role of ophthalmology and ocular oncology centers. Local disease management remains essential as systemic options develop.

Unresectable or metastatic disease is projected to grow at an 8.67% CAGR through 2032. Tebentafusp reported a 16% five-year survival rate, compared with 8% in the control arm, among eligible first-line metastatic patients. Darovasertib plus crizotinib reduced progression risk by 58% in OptimUM-02. These developments may expand systemic options for human leukocyte antigen (HLA)-A*02:01-negative patients and address evolving extrahepatic metastatic patterns.

Complete Report Scope:

  • By Disease Site
    • Uveal Melanoma
    • Conjunctival Melanoma
  • By Disease Stage
    • Primary Ocular Melanoma
    • Unresectable or Metastatic Ocular Melanoma
    • Other Metastatic Sites
  • By Treatment Type
    • Radiation Therapy
    • Surgical Therapy
    • Laser Therapy
    • Immunotherapy
    • Chemotherapy
    • Targeted Therapy
    • Other Treatment Type
  • By Drug Class
    • Immune Checkpoint Inhibitors
    • Protein Kinase Inhibitors
    • Immune Checkpoint Inhibitors
    • T-cell Receptor-Based Therapies
    • Other Drug Classes
  • By End User
    • Hospitals
    • Ophthalmology and Ocular Oncology Centers
    • Interventional Oncology Centers
    • Academic and Research Institutes
    • Other End Users
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 38.10% of the ocular melanoma market size in 2026. The region benefits from a strong network of Risk Evaluation and Mitigation Strategy (REMS)-certified centers and National Cancer Institute (NCI)-designated cancer centers with ocular oncology programs. KIMMTRAK generated USD 257.0 million in net sales in the United States in 2025. U.S. institutions are conducting combination studies, including percutaneous hepatic perfusion (PHP) followed by tebentafusp at Moffitt and neoadjuvant tebentafusp at Thomas Jefferson University. Major centers are increasingly integrating molecular risk assessment into treatment workflows. Canada and Mexico contribute to regional demand, although access remains subject to Health Canada and Federal Commission for Protection against Sanitary Risks (COFEPRIS) review timelines.

Asia-Pacific is projected to grow at a compound annual growth rate (CAGR) of 8.95% through 2032. China, Japan, South Korea, and Australia are expanding specialized ophthalmic oncology capacity and participation in global clinical studies. China holds the largest position in the region, supported by expanding oncology resources and approvals of novel immunotherapies. Japan contributes through its immunotherapy expertise and participation in international trials. The lower frequency of human leukocyte antigen (HLA)-A*02:01 limits the eligible population for tebentafusp in parts of the region. This increases the relevance of HLA-agnostic development programs as they progress toward potential approvals. A 2026 meta-analysis reported pooled sensitivity of 78.21% and specificity of 94.28% for machine-learning and deep-learning diagnostic models, while ultrasound-based models achieved an area under the curve (AUC) of 0.984.

Europe is the second-largest regional market, and KIMMTRAK generated USD 131.4 million in European net sales during 2025, representing 79% year-over-year growth. In January 2025, the National Institute for Health and Care Excellence (NICE) recommended tebentafusp for eligible National Health Service (NHS) England patients, subject to a commercial arrangement. CHEMOSAT guidance under the 2026 European Society for Medical Oncology (ESMO)-European Reference Network for Rare Adult Solid Cancers (EURACAN) framework supports broader consideration of percutaneous hepatic perfusion (PHP) in European treatment systems. Brazil approved KIMMTRAK under its rare diseases pathway in March 2025, creating the first regulatory authorization for metastatic uveal melanoma in Latin America. The Gulf Cooperation Council (GCC) may emerge as an additional access area as Saudi Arabia expands oncology infrastructure through its health investment program. South Africa’s academic cancer centers provide an established base for early adoption when approved systemic therapies become available.



List of Companies Covered in this Report:

  1. Agenus
  2. AstraZeneca
  3. Aura Biosciences, Inc.
  4. BeiGene, Ltd.
  5. Bristol-Myers Squibb
  6. Castle Biosciences, Inc.
  7. Daiichi Sankyo
  8. Delcath Systems, Inc.
  9. Eli Lilly and Company
  10. Roche
  11. Genmab
  12. IDEAYA Biosciences, Inc.
  13. Immunocore Holdings plc
  14. Incyte
  15. Iovance Biotherapeutics, Inc.
  16. Merck
  17. Novartis
  18. Pfizer
  19. Regeneron Pharmaceuticals
  20. Replimune Group, Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Expanding Use of Liver-Directed Therapy for Hepatic-Dominant Metastases
4.2.2 Rising Adoption of Biomarker-Guided Immunotherapy
4.2.3 Shift From Enucleation Toward Globe-Sparing Radiotherapy
4.2.4 Increasing Use of Molecular Prognostic Testing
4.2.5 Growing Clinical-Trial and Precision-Oncology Investment
4.2.6 Earlier Detection Through Multimodal Ocular Imaging
4.3 Market Restraints
4.3.1 Extreme Disease Rarity and Concentrated Specialist Capacity
4.3.2 HLA-A*02:01 Eligibility Limits for Tebentafusp
4.3.3 High Procedure Complexity and REMS-Linked Delivery Burden
4.3.4 Limited Evidence for Adjuvant and Combination Treatment Pathways
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
5.1 By Disease Site
5.1.1 Uveal Melanoma
5.1.2 Conjunctival Melanoma
5.2 By Disease Stage
5.2.1 Primary Ocular Melanoma
5.2.2 Unresectable or Metastatic Ocular Melanoma
5.2.3 Other Metastatic Sites
5.3 By Treatment Type
5.3.1 Radiation Therapy
5.3.2 Surgical Therapy
5.3.3 Laser Therapy
5.3.4 Immunotherapy
5.3.5 Chemotherapy
5.3.6 Targeted Therapy
5.3.7 Other Treatment Type
5.4 By Drug Class
5.4.1 Immune Checkpoint Inhibitors
5.4.2 Protein Kinase Inhibitors
5.4.3 Immune Checkpoint Inhibitors
5.4.4 T-cell Receptor-Based Therapies
5.4.5 Other Drug Classes
5.5 By End User
5.5.1 Hospitals
5.5.2 Ophthalmology and Ocular Oncology Centers
5.5.3 Interventional Oncology Centers
5.5.4 Academic and Research Institutes
5.5.5 Other End Users
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 India
5.6.3.3 Japan
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 Agenus Inc.
6.3.2 AstraZeneca PLC
6.3.3 Aura Biosciences, Inc.
6.3.4 BeiGene, Ltd.
6.3.5 Bristol-Myers Squibb Company
6.3.6 Castle Biosciences, Inc.
6.3.7 Daiichi Sankyo Company, Limited
6.3.8 Delcath Systems, Inc.
6.3.9 Eli Lilly and Company
6.3.10 F. Hoffmann-La Roche Ltd
6.3.11 Genmab A/S
6.3.12 IDEAYA Biosciences, Inc.
6.3.13 Immunocore Holdings plc
6.3.14 Incyte Corporation
6.3.15 Iovance Biotherapeutics, Inc.
6.3.16 Merck & Co., Inc.
6.3.17 Novartis AG
6.3.18 Pfizer Inc.
6.3.19 Regeneron Pharmaceuticals, Inc.
6.3.20 Replimune Group, Inc.
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
7.1 White-Space and Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Agenus Inc.
  • AstraZeneca PLC
  • Aura Biosciences, Inc.
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Castle Biosciences, Inc.
  • Daiichi Sankyo Company, Limited
  • Delcath Systems, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • IDEAYA Biosciences, Inc.
  • Immunocore Holdings plc
  • Incyte Corporation
  • Iovance Biotherapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Replimune Group, Inc.